Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Form SC 13G ARYA Sciences Acquisitio Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G Decarbonization Plus Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G Big Sky Growth Partners, Filed by: Farallon Capital Partners, L.P.
-
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
-
Affinia Therapeutics Closes $110 Million Series B Financing
-
Form SC 13G Khosla Ventures Acquisit Filed by: Farallon Capital Partners, L.P.
-
Exscientia Announces Investment of up to $525M
-
Toshiba must seek suitors, another big shareholder says, after CVC's $21 billion offer
-
LUMICKS Raises $93 Million in Series D Financing
-
Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies
-
Exclusive: Toshiba CEO faced board ouster before $20 billion buyout offer - sources
-
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
-
Toshiba CEO to step down as board meets Wednesday to consider his future: source
-
Farallon Comments on Privatization Proposal to Toshiba by CVC
-
Toshiba faces investor call to seek alternatives to CVC bid
-
Better Therapeutics to Become Publicly Traded via Merger with Mountain Crest Acquisition Corp. II (MCAD)
-
Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II
-
Form SC 13G Khosla Ventures Acquisit Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
SomaLogic to Combine with SPAC CM Life Sciences II (CMIIU)
-
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform
-
Form SC 13G Longboard Pharmaceutical Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Activist-backed proposal for Toshiba probe received 58% of shareholder votes
-
Shareholder Votes at Toshiba EGM Represent Clear Mandate for Greater Transparency and Accountability
-
Toshiba shareholders vote for probe in landmark win for Japan corporate governance
-
Ventyx Biosciences Doses First Subject in a Phase 1 Trial of VTX-958, a Selective Allosteric TYK2 Inhibitor for Autoimmune Diseases
-
Activist Toshiba shareholders tipped to win crucial vote on independent probe this week
-
POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I (RACA)
-
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
-
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
-
Farallon Urges Toshiba Shareholders to Make Their Voices Heard at Upcoming EGM
-
Form D/A FARALLON CAPITAL OFFSHOR
-
Form D/A Farallon Capital Partner
-
Form D/A Farallon Capital (AM)
-
Form D/A Farallon Capital Institu
-
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
-
Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs
-
Top Toshiba shareholder gets further support for proposed investigation
-
Glass Lewis Recommends Toshiba Shareholders Vote FOR Farallon Proposal
-
CORRECTING and REPLACING Glass Lewis Recommends Toshiba Shareholders Vote FOR Farallon Proposal
-
BlackRock builds 5% stake in Toshiba, becomes third largest shareholder
-
Farallon Comments on ISS Report Confirming Need for Toshiba to Rebuild Investor Trust
-
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
-
Proxy adviser ISS backs shareholder proposal for Toshiba investigation
-
U.S. hedge fund Farallon accuses Toshiba of 'backpedaling' on strategy
-
Farallon Capital Management Issues Letter to Toshiba Shareholders
-
eGenesis Announces $125 Million Series C Financing
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
-
Top Toshiba shareholder renews call for probe over AGM vote

